ArticleMolecular imaging and biology2010
Volume-normalized uptake rates with robust transportability from PET dual-time and Patlak analyses.
Article in Molecular imaging and biology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe intention here is to enhance the usefulness of the Gjedde-Patlak plot of dynamic positron emission tomography (PET) tracer uptake. Two additional parameters closely related to the physiologically significant and diagnostically useful phosphorylation rate k (3) are therefore studied. Additionally, their inter-institutional transportability is examined.
methodsThe two traditional parameters obtained from a Patlak plot are its slope Ki and its usually ignored tissue/plasma (=Q/Cp) axis intercept V. As a useful result, a normalized uptake rate may be defined as k=Ki /V. This is can be theoretically close to k (3). Similar to this an alternative normalized uptake rate is defined as k (3)' =Ki /V '. Here, V ' would be a composite of model rate constants, reasonably known a priori, and the measured V so as to depend less on errors in the latter. Parameter determination demonstrations utilize data from the 2-deoxy-2-[F-18]fluoro-D-glucose(FDG)-PET literature.
resultsUsing median k (i) values from 24 FDG dynamic studies and algebraic relationships, on average: k=1.07 k (3)(r=0.97), and k (3)' =0.95k (3) (r=0.91). A skeletal muscle case also demonstrates agreements with k (3). For liver malignancies k and k (3)' can be diagnostically slightly superior to Ki. Unaffected by institutionally dependent Q and Cp calibrations and methods, these can be more robust than Ki in a number of circumstances.
conclusionTwo studied physiologically meaningful parameters, close to the diagnostically important k (3), can supplement Ki and enhance Patlak analysis by appropriately utilizing normally ignored information. Hitherto, k (3) was obtainable only by complex nonlinear least squares compartmental model analysis. The additional parameters can have more robust inter-institutional transportability than Ki.
Indexed as
Identifiers
19949982What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.